SCHEMBL2372209

SCHEMBL2372209

OCc1cc(-c2cccnc2F)ccc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 2/20 0.48
DHODH Q02127 4/20 0.47
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
MAP2K4 P45985 1/20 0.44
MAPKAPK2 P49137 1/20 0.44
MAPKAPK3 Q16644 1/20 0.44
MAPK6 Q16659 1/20 0.44
LRRK2 Q5S007 1/20 0.41
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
ERN1 O75460 1/20 0.39
CYP11B1 P15538 1/20 0.39
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
CYP2C19 P33261 1/20 0.38
GRIA2 P42262 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
METAP2 P50579 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16675779 0.77 PRKCI (0.51) CYP11B2DHODHMAPTMAP2K4LRRK2
SCHEMBL3875252 0.75 CYP11B2 (0.55) CYP11B2DHODHMAPTGSK3BCYP11B1
SCHEMBL22230844 0.75 CYP11B2 (0.47) CYP11B2DHODHMAPTCYP11B1MAOA
SCHEMBL4277167 0.75 LRRK2 (0.37) CYP11B2MAPK1MAP2K4MAPKAPK2MAPKAPK3
SCHEMBL3881160 0.75 CYP11B2 (0.50) CYP11B2DHODHMAPTGSK3BCYP11B1
SCHEMBL2371460 0.73 ERN1 (0.53) CYP11B2DHODHMAPTERN1CYP11B1
SCHEMBL30316707 0.73
SCHEMBL3876408 0.73 DHODH (0.50) CYP11B2DHODHMAPTCYP11B1MAOA
SCHEMBL344036 0.73
SCHEMBL31051044 0.73 DHODH (0.50) CYP11B2DHODHMAPTCYP11B1MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP CYP11B2 1818/4885DHODH 1586/4885MAPT 753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.